Papers

Gastric intestinal metaplasia: subtypes and natural history

H M T El-Zimaity, J Ramchatesingh, M Ali Saeed, D Y Graham

Abstract

Background—It has been suggested that the subtyping of intestinal metaplasia in the stomach is useful in stratifying patients with regard to risk of developing gastric cancer.

Aim—To determine whether subtyping intestinal metaplasia provided useful information regarding the natural history of intestinal metaplasia.

Methods—The study used large cup gastric biopsy specimens from predetermined locations (gastric mapping). Follow up biopsies were obtained at one, two, and/or nine years. Biopsies with intestinal metaplasia were stained with high iron diamine/Alcian blue (HID/AB) to determine whether they expressed neutral mucins, sialomucins, or sulphomucins.

Results—Seventy nine patients with intestinal metaplasia were studied and characterised with regard to the most advanced subtype of intestinal metaplasia. The most severe type of intestinal metaplasia was type II in 33 patients and type III in 34 patients. *Helicobacter pylori* was cured in 67 patients. Follow up showed that changes in type of metaplasia (apparent regression or progression) occurred in both directions and were independent of *H pylori* status. For example, biopsy sites with “loss” of metaplasia at a follow up visit might have it “reappear” at a subsequent visit. During follow up, no patient developed gastric dysplasia or died from gastric cancer.

Conclusion—HID subtyping did not provide useful information to the clinician or the pathologist. The data are consistent with the notion that the pattern, extent, and severity of atrophy with/without intestinal metaplasia is a far more important predictor of increased cancer risk than intestinal metaplasia subtype.

(J Clin Pathol 2001;54:679–683)

Keywords: *Helicobacter pylori*; intestinal metaplasia; high iron diamine; gastric cancer

Intestinal-type gastric carcinoma is frequently accompanied by widespread intestinal metaplasia. Gastric cancer is believed to arise via a multi-stage process that includes chronic gastritis, gastric atrophy, usually with intestinal metaplasia, and finally dysplasia.^{1–8} It remains unclear whether intestinal metaplasia is a premalignant condition or a marker for increased risk of malignancy.^{2–9–10} The fact that intestinal metaplasia in

the antrum is also found with duodenal ulcer disease, a condition associated with a low risk for the development of gastric cancer, suggests that other conditions or events are important in the pathogenesis of gastric cancer.^{11–12}

The risk of developing gastric adenocarcinoma is highest in those with the most extensive atrophy associated with hypochlorhydria or achlorhydria.^{13–15} It has been suggested that there is a relation between cancer risk and the subtype of intestinal metaplasia, with the incidence of cancer being highest among patients with intestinal metaplasia subtype III.^{16–21} Confirmation of this hypothesis would suggest that typing of intestinal metaplasia could provide a simple approach to identify those at highest risk, and would allow resources to be directed to surveillance of that small group. Our study was designed to ask whether the results regarding the presence and type of intestinal metaplasia are reproducible or consistent on follow up of the same individual and whether type III metaplasia led to a high frequency of dysplasia.²²

Materials and methods

PATIENTS

Mucosal biopsy specimens were obtained from patients who had previous upper gastrointestinal endoscopy with gastric mapping. Cases included patients with documented intestinal metaplasia who received surveillance endoscopy at six to 12 month intervals for up to nine years, and included patients in whom *Helicobacter pylori* infection had been treated successfully, in addition to treatment failures. Indications for upper gastrointestinal endoscopy included duodenal ulcer disease, gastric ulcer, non-ulcer dyspepsia, suspected mucosa associated lymphoid tissue lymphoma, volunteers, gastro-oesophageal reflux disease, or a previous diagnosis of intestinal metaplasia.

BIOPSY SPECIMENS

Each specimen was placed in a separate bottle of formalin and routinely processed. Serial sections were cut at 5 µm and stained with a triple stain, either the Genta stain²³ or El-Zimaity triple stain.^{24–25} Each specimen was reviewed by one pathologist and scored using a visual analogue scale from 0 (absent/normal) to 5 (maximal intensity) for *H pylori* and intestinal metaplasia.²⁶

HIGH IRON DIAMINE STAINING

Biopsies with intestinal metaplasia were stained with high iron diamine/Alcian blue (HID/AB) to identify neutral mucins, sialomucins, and sulphomucins. Briefly, slides were immersed in

Gastrointestinal
Mucosa Pathology
Laboratory, VA
Medical Center and
Baylor College of
Medicine, Houston,
Texas 77030, USA
H M T El-Zimaity
J Ramchatesingh
D Y Graham

Department of
Medicine, VA Medical
Center and Baylor
College of Medicine
M Ali Saeed

Correspondence to:
Dr El-Zimaity,
Gastrointestinal Mucosa
Pathology Laboratory, Rm
3A352, VA Medical Center
(111-D), 2002 Holcombe
Blvd, Houston, Texas 77030,
USA
hziimaity@bcm.tmc.edu

Accepted for publication
7 February 2001

Figure 1 Gastric map showing biopsy sites. The letters A, B, and C refer to antrum, body, and cardia, respectively. The number after the letter (for example, A3) refers to specific sites.

HID solution for 18 to 20 hours, at 23–25°C. Slides were then rinsed with deionised water and stained with 1% Alcian blue (pH 2.5) for two minutes.²⁷ The evaluation of sialomucins and sulphomucins was done in sections without haematoxylin counterstain. Subtyping intestinal metaplasia was done according to the system used by Jass and Filipe^{17–22} as follows.

METAPLASIA SUBTYPING

Complete intestinal metaplasia

Type I: non-secretory absorptive cells and sialomucin secreting goblet cells.

Incomplete intestinal metaplasia

Type II: few absorptive cells, columnar cells secreting neutral and acid sialomucin, and goblet cells secreting mainly sialomucin but occasionally sulphomucin.

Type III: columnar cells secreting predominantly sulphomucin and goblet cells secreting sialomucin or sulphomucin.

ANALYSES

Patients were classified according to the most incomplete type of intestinal metaplasia. In addition, the change (apparent progression or regression) of intestinal metaplasia was analysed by site. Patients with more than five biopsies from the same sites obtained at multiple visits were further grouped with regard to the regions involved (antrum only *v* antrum and body). All scores were entered into a database and analysed using SigmaStat 2.03 (SPSS, Chicago, Illinois, USA). Fisher's exact test or, when appropriate, the χ^2 test (both two tailed) were used for comparison of proportions. Significance of differences and relations were determined by p values of ≤ 0.05 .

Table 1 Intestinal metaplasia subtype follow up in patients cured of *Helicobacter pylori* infection

Subtype at day 1	N	Subtype	1 year (n)	2 years (n)	6–9 years (n)
III	34	0	8	3	1
		I or II	7	8	5
		III	18	2	3
		No biopsy	1	21	19
		Died	0	0	6
II	33	0	5	3	3
		I or II	23	7	3
		III	5	2	1
		No biopsy	0	21	21
		Died	0	0	5

Data are analysed by patient.

Results

PATIENTS

Seventy nine patients, five women and 74 men (median age, 60; range, 32–80 years) were studied. Sixty seven patients were cured of *H pylori* infection; 12 remained infected at follow up. Follow ups were available at one year (n = 74), two years (n = 28), and nine years (n = 36). Three to 12 large cup (RADIAL JAW; MicroVasive, Watertown, Massachusetts, USA) gastric biopsy specimens were obtained from predetermined locations (fig 1). The minimal set was three, consisting of two antral (sites A3 and A4) and one corpus biopsy (site B6).

PATIENTS NEGATIVE FOR *H PYLORI* AT FOLLOW UP

Sixty seven patients had a total of 1970 biopsies examined (average, 72/patient); 556 biopsies had intestinal metaplasia and were evaluated with HID/AB. Scoring was done according to the most advanced type of intestinal metaplasia. At the first visit, subtype II was present in 33 patients and subtype III was present in 34 patients (table 1).

One year follow up

Twenty three of the 33 patients initially classified with type II intestinal metaplasia had intestinal metaplasia type II at follow up; five had apparent regression to no intestinal metaplasia and five had undergone apparent progression to intestinal metaplasia type III.

Only 18 of the 33 patients initially classified as intestinal metaplasia type III had type III intestinal metaplasia at one year; 15 had apparently “regressed”, with eight having no metaplasia and seven having intestinal metaplasia type II.

Two year follow up

Twelve patients initially classified as type II intestinal metaplasia were evaluated two years after treatment. Type II intestinal metaplasia was present in seven; two had “progressed” to type III and three had no metaplasia found.

Thirteen of 34 patients initially classified as type III were evaluated after two years; no metaplasia was found in three and eight had regressed to intestinal metaplasia type II.

Nine year follow up

Five of the 33 patients initially classified as type II intestinal metaplasia died of unrelated diseases. Seven patients were evaluated at the nine year follow up: three had no metaplasia, three had intestinal metaplasia type II, and one had intestinal metaplasia type III.

Six of the 34 patients initially classified as type III intestinal metaplasia died of unrelated illnesses. Nine patients were evaluated and one had no metaplasia, five had intestinal metaplasia type II, and three had intestinal metaplasia type III.

PATIENTS WITH PERSISTENT *H PYLORI* INFECTION

Twelve patients had persistent *H pylori* infection. A total of 250 biopsies were examined (average, 21/patient); 56 biopsies had intestinal metaplasia and were evaluated with HID/AB.

Table 2 Follow up of intestinal metaplasia subtypes in treatment failures

Subtype at day 1	n	Subtype	1 year (n)	2 years (n)	6-9 years (n)
III	6	0	1		1
		I or II	1	2	1
		III	4	1	0
		No biopsy	0	3	2
		Died	0	0	2
II	6	0	1		2
		I or II	1		2
		III			1
		No biopsy	4		1
		Died	0		0

Data are analysed by patient.

Table 2 summarises the data. Six patients were initially classified as type III. At one year follow up, four continued to have type III intestinal metaplasia and two regressed to no metaplasia or type II intestinal metaplasia. At nine years, two of the six remaining patients had died of unrelated causes. Two were re-evaluated and one had no metaplasia and one had intestinal metaplasia type II. Six of these patients were initially classified as having intestinal metaplasia type II. Two were evaluated at one year follow up and one had no metaplasia and one had intestinal metaplasia type II. Five patients were evaluated after nine years and two continued to have intestinal metaplasia subtype II, one had apparent progression to type III, and two had no metaplasia.

ANALYSIS BY BIOPSY SITE

At the first visit, 28 of 202 biopsies (14%) were type I, 109 (54%) were type II, and 65 (32%) were type III. Changes in type of metaplasia in both directions were seen independent of the presence or absence of *H pylori*. For example, in 11% of biopsy sites, metaplasia disappeared at one follow up visit but reappeared at a subsequent visit (table 3).

ANALYSIS ACCORDING TO REGION

To obtain a better representation of the distribution of intestinal metaplasia we performed a subgroup analysis restricted to 39 patients with more than five biopsies obtained at multiple visits, including 29 cured of the infection and 10 with persistent infection. The data were analysed according to the two working hypotheses: the presence of intestinal metaplasia in both the antrum and corpus has a worse prognosis than presence in the antrum only, and intestinal metaplasia with a visual analogue scale score of 5 is worse than that with a visual analogue scale of 1.

Table 3 Changes in type of metaplasia in both directions were seen independent of the presence of *Helicobacter pylori* or cure of the infection

Patient	Visit	A1	A2	A3	A4	A5
A	Day 0	III	0	I	II	II
	1 month	0	II	II	0	II
	6 months	0	II	0	I	0
	1 year	0	0	II	0	0
B	Day 0	III	II	III	III	III
	2 months	I	I	I	I	ND
	8 months	III	I	III	II	ND
	1 year	III	III	II	III	II

A1-5 correspond to biopsy sites in the antrum.

Numbers given in columns are the type of metaplasia identified at that visit.

ND, not determined.

Patients cured of *H pylori* infection

After *H pylori* eradication, intestinal metaplasia status regressed in 18 patients, eight of whom initially had incomplete intestinal metaplasia type III. Apparent regression occurred irrespective of initial intestinal metaplasia subtype. Two patients had the same score before and after treatment with a 65 month follow up (intestinal metaplasia score was 4 and 5).

Patients with persistent *H pylori* infection

At presentation, all 10 patients had intestinal metaplasia in both the antrum and corpus and eight had intestinal metaplasia in both regions at subsequent visits. The two patients who did not appear to have intestinal metaplasia in subsequent visits had initial scores for intestinal metaplasia of 1.

Comparison of patients with intestinal metaplasia in both the antrum and corpus showed that the intestinal metaplasia status was unchanged in eight of 10 patients with persistent *H pylori* compared with 11 of 29 in whom the infection was cured ($p = 0.03$). When the comparison was done based on initial intestinal metaplasia score, no significant difference was observed between groups. For example, 13 patients who were subsequently cured of the infection had an initial intestinal metaplasia score ≥ 3 . On follow up, four showed apparent regression, eight showed no change, and one showed apparent progression. By comparison, in the untreated group, five had an initial intestinal metaplasia score ≥ 3 . No changes were seen in any of the patients ($p = 0.27$).

Discussion

The association between gastric intestinal metaplasia and adenocarcinoma of the stomach is well known.¹⁻²⁸ Because the development of gastric carcinoma is slow and unpredictable, investigators have searched for premalignant markers of increased risk for gastric cancer. Intestinal metaplasia subtyped as III is often considered an ominous precursor lesion for the intestinal form of gastric cancer.¹⁶⁻¹⁹ Biopsy of the same areas of the stomach during follow up for up to nine years showed that neither the presence nor type of intestinal metaplasia was consistent, and that the type of metaplasia appeared to change in both directions. Areas of intestinal metaplasia (or a certain subtype) are generally small (fig 2), so that sampling error is probably responsible for the fact that an approximately equal number of studies have suggested that intestinal metaplasia regresses or does not regress after *H pylori* eradication.²²

²⁹⁻³⁰⁻³⁵ Sampling bias cannot be completely overcome by using targeted biopsies and jumbo forceps. Moreover, *H pylori* eradication did not decrease the likelihood of finding intestinal metaplasia in subsequent biopsies when comparisons were made between patients with the same initial score for intestinal metaplasia. Recent studies have shown that mucin protein expression is similar in types II and III intestinal metaplasia, so that examining the patterns of mucin protein expression cannot be used as a surrogate for the identification of type III intestinal metaplasia, and challenging the

Figure 2 In general, areas of intestinal metaplasia of a certain subtype are small and could easily go unsampled at follow up. (A) A small focus of intestinal metaplasia is seen in the middle of the section; El-Zimaity triple stain; original magnification, $\times 10$. (B) A small focus of intestinal metaplasia type III among type II intestinal metaplasia; high iron diamine, original magnification, $\times 10$.

hypothesis that type II intestinal metaplasia consistently evolves into type III.³⁶ Our study shows that, on follow up, typing intestinal metaplasia does not predict the pattern in subsequent biopsies or the outcome of the patient. Subsequent studies should probably examine both the type of intestinal metaplasia and mucin protein expression. The concept that type III intestinal metaplasia is predictive of a poor outcome has not been subjected to prospective trials and the natural history of the lesion is unknown. In our series, 18% of patients initially classified as intestinal metaplasia type III died of unrelated causes during follow up; none developed or died from gastric cancer. Only 20% of those with type III intestinal metaplasia had repeat biopsies showing type III intestinal metaplasia and none progressed to dysplasia or gastric carcinoma. These results appear to be different from those of Silva *et al*,²² who reported dysplasia on follow up of patients with type III intestinal metaplasia. However, they followed only eight patients for one year and three patients for five years. All those who developed dysplasia did so within the first year of the study, suggesting that it was probably present at the initial procedure.

In summary, it is not currently possible to make recommendations or prognoses based on single or multiple biopsies showing type III intestinal metaplasia.³⁷ HID subtyping does not provide a reliable indicator of risk³⁷⁻³⁹ or provide prognostic value to the patient, the pathologist, or the endoscopist. Surveillance based solely on the presence of type III intestinal metaplasia appears unwarranted. The available data are consistent with the notion that the pattern, extent, and severity of atrophy with/without intestinal metaplasia are better predictors of risk than intestinal metaplasia

subtype.⁴⁰ The challenge to identify a reliable marker that further identifies a group as sufficiently high risk to justify endoscopic surveillance remains.

- Correa P, Cuello C, Duque E. Carcinoma and intestinal metaplasia of the stomach in Colombian migrants. *J Natl Cancer Inst* 1970;44:297-306.
- Correa P. A human model of gastric carcinogenesis. *Cancer Res* 1988;48:3554-60.
- Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—first American Cancer Society award lecture on cancer epidemiology and prevention. *Cancer Res* 1992;52:6735-40.
- Correa P. Clinical implications of recent developments in gastric cancer: pathology and epidemiology. *Semin Oncol* 1985;12:2-10.
- Correa P. The epidemiology of gastric cancer. *World J Surg* 1991;15:228-34.
- Watanabe T, Tada M, Nagai H, *et al*. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. *Gastroenterology* 1998;115:642-8.
- Parsonnet J, Friedman GD, Vandersteen DP, *et al*. Helicobacter pylori infection and the risk of gastric carcinoma. *N Engl J Med* 1991;325:1127-31.
- Correa P, Duque E, Duque E, *et al*. Gastric cancer in Colombia. III. Natural history of precursor lesions. *J Natl Cancer Inst* 1976;57:1027-35.
- Hattori T. Development of adenocarcinomas in the stomach. *Cancer* 1996;57:1528-34.
- Miehlke S, Hackelsberger A, Meining A, *et al*. Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. *Br J Cancer* 1998;78:263-6.
- Sobala GM, O'Connor HJ, Dewar EP, *et al*. Bile reflux and intestinal metaplasia in gastric mucosa. *J Clin Pathol* 1993;46:235-40.
- Robles-Campos R, Lujan-Mompean JA, Parrilla-Paricio P, *et al*. Role of Helicobacter pylori infection and duodenogastro reflux in the pathogenesis of alkaline reflux gastritis after gastric operations. *Surg Gynecol Obstet* 1993;176:594-8.
- Stolte M, Meining A. Helicobacter pylori and gastric cancer. *Oncologist* 1998;3:124-8.
- Sipponen P, Kekki M, Seppala K, *et al*. The relationships between chronic gastritis and gastric acid secretion. *Aliment Pharmacol Ther* 1996;10(suppl 1):103-18.
- Lechago J, Correa P. Prolonged achlorhydria and gastric neoplasia: is there a causal relationship [editorial]? *Gastroenterology* 1993;104:1554-7.
- Filipe MI, Nunoz N, Matko I, *et al*. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. *Int J Cancer* 1994;57:324-9.
- Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. *Gut* 1991;32:1110-13.
- Huang C-B, Xu J, Huang JF, *et al*. Sulphomucin colonic type intestinal metaplasia and carcinoma in the stomach: a histochemical study of 115 cases obtained by biopsy. *Cancer* 1986;57:1370-5.
- Filipe MI, Potet F, Bogomoletz WV, *et al*. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. *Gut* 1985;26:1319-26.
- Turani H, Lurie B, Chaimoff Ch, *et al*. The diagnostic significance of sulfated acid mucin content in gastric intestinal metaplasia with early gastric cancer. *Am J Gastroenterol* 1986;81:343-5.
- Craanen ME, Blok P, Dekker W, *et al*. Prevalence of subtypes of intestinal metaplasia in gastric antral mucosa. *Dig Dis Sci* 1991;36:1529-36.
- Silva S, Filipe MI, Pinho A. Variants of intestinal metaplasia in the evolution of chronic atrophic gastritis and gastric ulcer. A follow up study. *Gut* 1990;31:1097-104.
- Genta RM, Robason GO, Graham DY. Simultaneous visualization of Helicobacter pylori and gastric morphology: a new stain. *Hum Pathol* 1994;25:221-6.
- El-Zimaity HMT, Ota H, Scott S, *et al*. A new triple stain for Helicobacter pylori suitable for the autostainer. *Arch Pathol Lab Med* 1998;122:732-6.
- El Zimaity HM. Modified triple stain (carbol fuchsin/Alcian blue/hematoxylin-eosin) for the identification of Helicobacter pylori. *Arch Pathol Lab Med* 2000;124:1417.
- El-Zimaity HM, Graham DY, Al-Assi MT, *et al*. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. *Hum Pathol* 1996;27:35-41.
- Spicer SS. Diamine methods for differentiating mucosubstances histochemically. *J Histochem Cytochem* 1965;13:211-34.
- Ihamaki T, Sipponen P, Varis K, *et al*. Characteristics of gastric mucosa which precede occurrence of gastric malignancy: results of long-term follow-up of three family samples. *Scand J Gastroenterol Suppl* 1991;186:16-23.
- Siurala M, Lehtola J, Ihamaki T. Atrophic gastritis and its sequelae. Results of 19-23 years' follow-up examinations. *Scand J Gastroenterol* 1974;9:441-6.
- Rosch W, Demling L, Elster K. Is chronic gastritis a reversible process? Follow-up study of gastritis by step-wise biopsy. *Acta Hepatogastroenterol (Stuttg)* 1975;22:252-5.

- 31 Maaroos H-I, Salupere V, Uibo R, *et al.* Seven-year follow-up study of chronic gastritis in gastric ulcer patients. *Scand J Gastroenterol* 1985;20:198-204.
- 32 Ihamaki T, Kekki M, Sipponen P, *et al.* The sequelae and course of chronic gastritis during a 30- to 34-year bioptic follow-up study. *Scand J Gastroenterol* 1985;20:485-91.
- 33 Villako K, Kekki M, Maaroos H-I, *et al.* Chronic gastritis: progression of inflammation and atrophy in a six-year endoscopic follow-up of a random sample of 142 Estonian urban subjects. *Scand J Gastroenterol* 1991;26:135-41.
- 34 Niemela S, Karttunen T, Kerola T. Helicobacter pylori-associated gastritis. Evolution of histologic changes over 10 years. *Scand J Gastroenterol* 1995;30:542-9.
- 35 Valle J, Kekki M, Sipponen P, *et al.* Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. *Scand J Gastroenterol* 1996;31:546-50.
- 36 Reis CA, David L, Correa P, *et al.* Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. *Cancer Res* 1999;59:1003-7.
- 37 Ramesar KCRB, Sanders DSA, Hopwood D. Limited value of type III intestinal metaplasia in predicting risk of gastric carcinoma. *J Clin Pathol* 1987;40:1287-90.
- 38 Oohara T, Tohma H, Aono G, *et al.* Intestinal metaplasia of the regenerative epithelia in 549 gastric ulcers. *Hum Pathol* 1983;14:1066-71.
- 39 Kato Y, Kitagawa T, Yanagisawa A, *et al.* Site-dependent development of complete and incomplete intestinal metaplasia types in the human stomach. *Jpn J Cancer Res* 1992;83:178-83.
- 40 Sugano H, Nakamura K, Kato Y. Pathological studies of human gastric cancer. *Acta Pathol Jpn* 1982;32:329-47.

7th European Forum on Quality Improvement in Health Care

21-23 March 2002

Edinburgh, Scotland

We are delighted to announce this forthcoming conference in Edinburgh. Authors are invited to submit papers (call for papers closes on **Friday 5 October 2001**) and delegate enquiries are welcome.

The themes of the Forum are:

- Leadership, culture change, and change management
- Achieving radical improvement by redesigning care
- Health policy for lasting improvement in health care systems
- Patient safety
- Measurement for improvement, learning, and accountability
- Partnership with patients
- Professional quality: the foundation for improvement
- Continuous improvement in education and training
- People and improvement.

Presented to you by the BMJ Publishing Group (London, UK) and Institute for Healthcare Improvement (Boston, USA). For more information contact: quality@bma.org.uk or look at the website www.quality.bmjpg.com. Tel: +44 (0)20 7383 6409; fax: +44 (0)20 7373 6869.